Oct. 13, 2026
Choosing a suitable immunogen is one of the most important early decisions in a nanobody discovery project. We help research and biotechnology teams assess antigen format, preparation requirements, and quality checks before immunization, so the material is aligned with the intended target and downstream application. The right plan depends on what the nanobody must recognize, how the target behaves in its biological context, and which animal and assay requirements apply. This guide explains the decisions to make and the information to share when evaluating an immunogen preparation service.
This guide is for veterinary medicine researchers, biotech teams, and procurement professionals planning a nanobody discovery project. It is also useful if you have a target sequence or protein but are unsure whether it is suitable for immunization. We focus on preparation decisions rather than promising that any single antigen format will produce a successful binder. Discovery outcomes depend on multiple biological and experimental factors.
Immunogen preparation is the process of obtaining or producing target material, preparing it in a suitable form, and checking whether it meets agreed project requirements before it is used for immunization. For nanobody discovery, the immunogen may be a purified protein, a protein domain, a peptide, a protein complex, or a cell-based preparation. The best choice is determined by the target’s structure and the binding characteristics sought. For example, a nanobody intended to bind a native cell-surface target may require an antigen format that preserves relevant extracellular features.
Antibodies recognize molecular features called epitopes, which may be linear stretches of amino acids or structures formed by a folded protein. A short peptide can represent a defined sequence, but it may not reproduce a conformational epitope that depends on the full protein’s three-dimensional structure. Conversely, a full-length protein may include regions that are not accessible in the intended assay. A nanobody is a single-domain antibody fragment, commonly around 12–15 kDa, and its desired binding behavior should guide antigen design rather than molecular size alone.
| Immunogen format | Potential fit | Points to assess |
|---|---|---|
| Purified full-length protein | Targets with accessible, stable purified forms | Folding, aggregation, tags, and similarity to the native target |
| Protein domain or fragment | Targets with a defined functional or accessible region | Whether the fragment retains the epitope and relevant structure |
| Synthetic peptide | Defined linear sequences or selected regions | Peptide length, solubility, conjugation, and native-context relevance |
| Cell-based or complex antigen | Targets that depend on membrane context or molecular partners | Target expression, background components, and assay compatibility |
Veterinary projects may involve proteins from companion animals, livestock, poultry, or pathogens relevant to animal health. Sequence variation between species or strains can affect whether a candidate antigen represents the intended target. We recommend confirming the target species, sequence accession or sequence file, and intended use before selecting a construct. If cross-reactivity is important, define which species or variants should be included in later evaluation.
Start by describing where and how the nanobody will be used, such as a diagnostic assay, research reagent, imaging workflow, or functional study. Clarify whether binding is needed to a purified protein, a native cell-surface target, or a target in a complex sample. This helps determine whether a peptide, fragment, soluble protein, or cell-based antigen is the most appropriate starting point. It also highlights assay-specific requirements that may not be visible from the target sequence alone.
Share the target name, species, sequence information, domain boundaries, known isoforms, and any relevant post-translational modifications. If a commercial or in-house protein is available, provide its construct design, tag information, buffer, and available analytical data. These details help identify mismatches between the immunogen and the target intended for downstream testing. For veterinary targets, include relevant strain or breed context when sequence differences may matter.
If you are looking for more details, kindly visit NBbiolab.
Quality checks should be selected according to the antigen and project risk. Common checks can include identity confirmation, purity assessment, concentration measurement, solubility or aggregation review, and formulation documentation. A project may set an example acceptance criterion of at least 90% purity, but this is not appropriate for every antigen and should be agreed in advance rather than assumed. For animal immunization, discuss endotoxin requirements with the project team because acceptable levels depend on the animal model, dose, route, and protocol.
Ask how results will be reported and what happens if the material does not meet the agreed criteria. A gel image or chromatographic profile may be useful, but the appropriate evidence depends on the analytical method and antigen type. For a small pilot, an aliquot of 1 mg may be a useful planning reference for discussing material needs, not a universal minimum or guaranteed service quantity. The actual amount should be calculated from the immunization plan, repeat testing, and anticipated downstream assays.
Formulation affects stability, solubility, and compatibility with immunization or analytical procedures. Discuss buffer composition, preservatives, storage temperature, shipping conditions, and freeze-thaw limitations before production or shipment. If an antigen contains a tag or carrier component, consider whether it could influence immune responses or later screening. We recommend documenting these choices in the project specification so that preparation and evaluation use consistent assumptions.
Pricing and lead time are determined by the work required, not simply by the target name. Relevant factors include whether the antigen is already available, whether expression or synthesis is needed, construct complexity, purification challenges, quality-control methods, and the number of formats or variants requested. Minimum quantity can also vary with the preparation route and the project’s planned use. We avoid treating a generic estimate as a commitment before reviewing these details.
To request a useful scope assessment, provide the target sequence or accession, desired antigen format, species, intended application, available starting material, quantity needs, and any acceptance criteria. Also state whether you need only immunogen preparation or coordinated support for a broader nanobody discovery workflow. A written scope should distinguish included preparation and testing from optional work, and should identify deliverables, assumptions, and factors that could affect timing.
At NBbiolab, we work with clients to review target information, discuss suitable immunogen options, and define preparation and quality-check requirements for nanobody discovery projects. Our role is to help establish a practical scope based on the target and intended application, rather than assume one format fits every project. Final feasibility, quantity, and timing should be confirmed after reviewing the project details and material requirements.
A suitable immunogen is the one that best represents the binding target required by your application and can be prepared and assessed against clear project criteria. Begin by defining the target species, intended binding context, antigen format, and downstream use; then agree on quality checks, quantity, formulation, and deliverables. For veterinary projects, include relevant species or strain variation early so that antigen selection and later evaluation are aligned. Share these details with NBbiolab to discuss an immunogen preparation scope tailored to your nanobody discovery needs.
If you are looking for more details, kindly visit Immunogen Preparation Service for Nanobody Discovery.
Previous: Why Choose Imidacloprid and Moxidectin Spot-on Solution for Dogs?
Next: Nanobody Discovery CRO Guide: Workflow, Services, and Deliverables
If you are interested in sending in a Guest Blogger Submission,welcome to write for us!
All Comments ( 0 )